The examination of effects of switching to GLP-1 analog liraglutide or adding on insulin glargine once daily for type 2 diabetes controlled insufficiently by DPP-4 inhibitors and other oral anti-diabetic agents combination (multicenter study).
Phase of Trial: Phase III
Latest Information Update: 01 Oct 2018
Price : $35 *
At a glance
- Drugs Insulin glargine (Primary) ; Liraglutide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms BOOST-G
- 01 Oct 2018 Results published in the Diabetes Therapy
- 31 Aug 2018 Status changed from active, no longer recruiting to completed.
- 20 Nov 2015 Status changed from recruiting to active, no longer recruiting, according to University Hospital Medical Information Network - Japan record.